Editorial |

Evaluating the Role of HPV Testing for Women With Equivocal Papanicolaou Test Findings

J. Thomas Cox, MD
JAMA. 1999;281(17):1645-1647. doi:10.1001/jama.281.17.1645.
Text Size: A A A
Published online


The 1988 Bethesda System for reporting cervical and vaginal cytologic diagnoses dramatically altered the diagnostic categories at the lower end of the cytologic spectrum. The primary impetus for this change was the diagnostic variability and clinical confusion inherent in the class 2 Papanicolaou (Pap) group, which included a spectrum of cellular changes that ranged from normal to definitive manifestations of human papillomavirus (HPV). If clinical confusion were to be diminished, it was clearly necessary to clarify the nature of each class 2 cellular change more specifically. Unfortunately, some atypia remained ambiguous and were designated atypical squamous cells of undetermined significance (ASCUS). The designation "undetermined" highlights the continuing dilemma regarding cells that have no distinguishing characteristics to further clarify their nature. The category has been a major clinical issue, with 2 to 3 million women given a diagnosis that generates uncertainty each year.1,2 The magnitude of the concern is highlighted by a major commitment by the National Cancer Institute to evaluate the best triage option for women with equivocal and low-grade Pap smears in a randomized trial that began in 1995 and will end in 2001.3

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 27

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles